Art. -Nr.: HY-101200

Linsidomine hydrochloride

(Synonyms: SIN-1 chloride)

Kundenbewertung

Based on 1 Customer Validation

Linsidomine hydrochloride (SIN-1 chloride) is a spontaneous ROS/RNS generator and peroxynitrite donor. Linsidomine hydrochloride is a vasodilator and platelet aggregation inhibitor. Linsidomine hydrochloride induces oxidative stress-induced chondrocyte apoptosis and necrosis. Linsidomine hydrochloride inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of Linsidomine hydrochloride shows protective effects on Zn²⁺ treated nerve cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.97%
CAS. Nr.: 16142-27-1
Formel: C₆H₁₁ClN₄O₂
Molecular Weight:206.63

Speicherung:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Linsidomine hydrochloride Chemical Structure

CAS. Nr.: 16142-27-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Annexin A Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

In Vitro

Linsidomine hydrochloride (0-5 mM; 0-24 h) reduces the activity of hypertrophic chondrocytes, induces hypertrophic chondrocyte necrosis and apoptosis of non-hypertrophic ATDC5 and C28/I2 cells^[1].
Linsidomine hydrochloride (30-1000 μM; 190 min) prevents Zn²⁺ induced neuronal death, but is eliminated by uric acid (HY-B2130)^[2].
Linsidomine hydrochloride (100-300 μM; 0-190 min) increases the production of reactive oxygen species and active nitrogen, inhibits the Zn²⁺ induced glutathione reductase inactivation and the increase of oxidized glutathione/total glutathione ratio in PC12 cells^[2].
Linsidomine hydrochloride (1 mM; 2-3 h) induces nuclear accumulation of Nrf2 in EAhy926 and HUVECs cells^[3].
Linsidomine hydrochloride (0-500 μM; 30 min) inhibits platelet-derived growth factor BB-induced cell migration and proliferation by annexin A2 in rat aortic smooth muscle cells^[4].
Linsidomine hydrochloride (1-5 mM, 24 h) induces the accumulation of LC3-II, and the formation of autophagosome, inducing autophagy in serum starved EAhy926 cell^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Hypertrophic chondrocytes
Concentration:

0-5 mM
Incubation Time:

24 h
Result:

Reduced cellular viability in a dose/time-dependent manner.

Cell Viability Assay^[2]

Cell Line:

PC12
Concentration:

30 μM-1 mM
Incubation Time:

3 h
Result:

Improved Zn²⁺-reduced cell viability (< 1 mM).
Inhibited cell viability with the dose more than 1 mM.

Western Blot Analysis^[4]

Cell Line:

serum starved EAhy926
Concentration:

0-5 mM
Incubation Time:

24 h
Result:

Improved expression of LC3-II.

In Vivo

Linsidomine hydrochloride (0.01-0.1 mg/kg; ip; 14 days) attenuates neointima formation in balloon-injured rat carotid arteries^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague Dawley rats with a balloon-injured carotid artery model^[4]
Dosage:

0.01-0.1 mg/kg
Administration:

ip, 14 days
Result:

Reduced the I/M (intima to media) ratio of the carotid artery in the group treated with 0.1 mg/kg/day.
Did not change the I/M ratio of the carotid artery in the group treated with 0.01 mg/kg/day.

Chemical Information

CAS. Nr. 16142-27-1
Appearance Solid
Molecular Weight 206.63
Formel C₆H₁₁ClN₄O₂
Color White to off-white
SMILES

NC1=C[N+](N2CCOCC2)=NO1.[Cl-]
Synonyms

SIN-1 chloride
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 50 mg/mL (241.98 mM; Need ultrasonic)

DMSO : 50 mg/mL (241.98 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8396 mL

24.1978 mL

48.3957 mL

5 mM

0.9679 mL

4.8396 mL

9.6791 mL

10 mM

0.4840 mL

2.4198 mL

4.8396 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.10 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. He Y, et al. 3-morpholinosydnonimine (SIN-1)-induced oxidative stress leads to necrosis in hypertrophic chondrocytes in vitro. Biomed Pharmacother. 2018 Oct;106:1696-1704. [Content Brief]

[2]. An JM, et al. Neuroprotective effect of 3-morpholinosydnonimine against Zn²⁺-induced PC12 cell death. Eur J Pharmacol. 2015 Feb 5;748:37-44. [Content Brief]

[3]. Mattart L, et al. The peroxynitrite donor 3-morpholinosydnonimine activates Nrf2 and the UPR leading to a cytoprotective response in endothelial cells. Cell Signal. 2012 Jan;24(1):199-213. [Content Brief]

[4]. Won KJ, et al. 3-morpholinosydnonimine participates in the attenuation of neointima formation via inhibition of annexin A2-mediated vascular smooth muscle cell migration. Proteomics. 2011 Jan;11(2):193-201. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	4.8396 mL	24.1978 mL	48.3957 mL	120.9892 mL
	5 mM	0.9679 mL	4.8396 mL	9.6791 mL	24.1978 mL
	10 mM	0.4840 mL	2.4198 mL	4.8396 mL	12.0989 mL
	15 mM	0.3226 mL	1.6132 mL	3.2264 mL	8.0659 mL
	20 mM	0.2420 mL	1.2099 mL	2.4198 mL	6.0495 mL
	25 mM	0.1936 mL	0.9679 mL	1.9358 mL	4.8396 mL
	30 mM	0.1613 mL	0.8066 mL	1.6132 mL	4.0330 mL
	40 mM	0.1210 mL	0.6049 mL	1.2099 mL	3.0247 mL
	50 mM	0.0968 mL	0.4840 mL	0.9679 mL	2.4198 mL
	60 mM	0.0807 mL	0.4033 mL	0.8066 mL	2.0165 mL
	80 mM	0.0605 mL	0.3025 mL	0.6049 mL	1.5124 mL
	100 mM	0.0484 mL	0.2420 mL	0.4840 mL	1.2099 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Linsidomine hydrochloride

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Transcription Factor-Targeted Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Antihypertensive Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Alle Annexin A Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Linsidomine hydrochloride Related Classifications

HY-101200 Related Classifications